NASDAQ:AMRN

Amarin (AMRN) Stock Price, News & Analysis

$0.85
-0.03 (-3.40%)
(As of 05/10/2024 ET)
Today's Range
$0.85
$0.90
50-Day Range
$0.82
$1.07
52-Week Range
$0.65
$1.49
Volume
1.28 million shs
Average Volume
1.04 million shs
Market Capitalization
$350.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.08

Amarin MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
27.1% Upside
$1.08 Price Target
Short Interest
Bearish
3.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Amarin in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.16) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.74 out of 5 stars

Medical Sector

839th out of 921 stocks

Pharmaceutical Preparations Industry

395th out of 428 stocks

AMRN stock logo

About Amarin Stock (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock Price History

AMRN Stock News Headlines

A.I. is a Tidal Wave - Here’s What to Buy
The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.
A.I. is a Tidal Wave - Here’s What to Buy
The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.
Here's what Wall Street expects from Amarin's earnings report
Amarin Q1 2024 Earnings Preview
AMRN Apr 2024 3.000 call
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
5/11/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
275
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$1.08
High Stock Price Target
$1.25
Low Stock Price Target
$1.00
Potential Upside/Downside
+27.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-59,110,000.00
Pretax Margin
-17.24%

Debt

Sales & Book Value

Annual Sales
$306.91 million
Book Value
$1.33 per share

Miscellaneous

Free Float
402,623,000
Market Cap
$350.10 million
Optionable
Optionable
Beta
1.96

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Patrick J. Holt (Age 51)
    President, CEO & Director
    Comp: $678.88k
  • Mr. Thomas Charles Reilly (Age 51)
    Executive VP, CFO & Global Head of HR
    Comp: $1.01M
  • Dr. Steven B. Ketchum Ph.D. (Age 59)
    Executive VP, President of Research & Development and Chief Scientific Officer
    Comp: $1.16M
  • Mr. Jonathan N. Provoost (Age 54)
    Executive VP, Chief Legal & Compliance Officer and Secretary
    Comp: $160.08k
  • Mr. Aaron D. Berg (Age 61)
    Executive VP & President of U.S.
    Comp: $1.26M
  • Mr. Jordan Zwick (Age 37)
    Senior VP of Corporate Business Development & Investor Relations
  • Mr. Laurent Abuaf
    President of Europe & Senior VP
  • Dr. Nabil Abadir
    Chief Medical Officer of Global Medical Affairs
  • Dr. David Keenan Ph.D.
    Executive VP of Technical Operations & President of Europe

AMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" AMRN shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they expect the company's stock price to reach $1.08 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2024?

Amarin's stock was trading at $0.87 at the beginning of 2024. Since then, AMRN shares have decreased by 2.0% and is now trading at $0.8525.
View the best growth stocks for 2024 here
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $56.52 million for the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative net margin of 18.96% and a negative trailing twelve-month return on equity of 9.48%. During the same quarter last year, the firm earned ($0.04) EPS.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's major shareholders?

Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Longitude Cayman Ltd. (0.57%), GSA Capital Partners LLP (0.36%), BNP Paribas Financial Markets (0.23%), LCM Capital Management Inc (0.20%), Simplicity Wealth LLC (0.11%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
This page (NASDAQ:AMRN) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners